Allogene CEO David Chang and new head of R&D Zachary Roberts

Up­dat­ed: Off-the-shelf cell ther­a­py pi­o­neer Al­lo­gene re­cruits a Kite vet to run R&D

Af­ter rid­ing out much of a rough year at In­stil Bio — capped by a de­ci­sion to pause and then scrap the lead tu­mor-in­fil­trat­ing lym­pho­cyte pro­gram and slash more than half the staff — Zachary Roberts will be ring­ing in the new year as the head of R&D at one of the pi­o­neers of off-the-shelf cell ther­a­pies.

Al­lo­gene chief David Chang of­fered me a pre­view of the switch, which sees Rafael Ama­do mak­ing his ex­it from Al­lo­gene in an an­tic­i­pat­ed change to a new — and so far still un­re­vealed — post in biotech.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA